Open Access

Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine

  • Authors:
    • Yue Yu
    • Fei Ding
    • Meng Gao
    • Yi Fu Jia
    • Le Ren
  • View Affiliations

  • Published online on: July 17, 2019     https://doi.org/10.3892/ol.2019.10627
  • Pages: 3065-3071
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Due to its rapid progression, metastasis and resistance to chemotherapy, pancreatic cancer is one of the most malignant tumor types to affect the digestive system. Gemcitabine chemotherapy is typically the first choice of treatment for advanced pancreatic cancer; however, chemoresistance is a major obstacle to successful treatment. In order to elucidate the underlying mechanisms of gemcitabine resistance in pancreatic cancer, the drug‑resistant cell line SW1990‑gemcitabine (SW1990‑GZ) was established using the human pancreatic cancer cell line SW1990. The IC50, resistance index and growth of SW1990 and SW1990‑GZ cells were also assessed using 3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphenyl‑2‑H‑tetrazolium bromide (MTT) assays. The cellular uptake of gemcitabine in SW1990 and SW1990‑GZ was measured using high performance liquid chromatography (HPLC). The protein expression of p53 was also assessed by western blot analysis. The results demonstrated that the IC50 of SW1990 and SW1990‑Gz was 0.07±0.0021 and 87.5±3.24 µg/ml, respectively, and that the resistance index ratio of SW1990‑Gz was 1,250. The growth rate of SW1990‑GZ cells was low compared with that of SW1990 cells. The HPLC results indicated that gemcitabine uptake was markedly reduced in SW1990‑GZ cells compared with in SW1990 cells at different time points. The protein expression of p53 was significantly higher in GEM‑resistant SW1990‑GZ cells compared with that in SW1990 cells (P<0.01). These results suggest that a human gemcitabine‑resistant pancreatic cancer cell line was successfully established, with stable and significant drug resistance. The results of the present study suggest that the decreased cellular uptake of gemcitabine may serve an important role in gemcitabine chemoresistance in SW1990‑GZ cells; thus, this cell line may be used as an effective in vitro model to improve our understanding of gemcitabine‑resistance in pancreatic cancer.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yu, Y., Ding, F., Gao, M., Jia, Y.F., & Ren, L. (2019). Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine. Oncology Letters, 18, 3065-3071. https://doi.org/10.3892/ol.2019.10627
MLA
Yu, Y., Ding, F., Gao, M., Jia, Y. F., Ren, L."Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine". Oncology Letters 18.3 (2019): 3065-3071.
Chicago
Yu, Y., Ding, F., Gao, M., Jia, Y. F., Ren, L."Establishment and characterization of the gemcitabine‑resistant human pancreatic cancer cell line SW1990/gemcitabine". Oncology Letters 18, no. 3 (2019): 3065-3071. https://doi.org/10.3892/ol.2019.10627